2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
24
Urinary Bladder Neoplasms
5
Neoplasms
2
Urothelial Bladder Cancer
1
Urologic Neoplasms
1
Urinary Bladder Diseases
1
Stomach Neoplasms
1
Recurrence
1
Prostate cancer, familial
1
Parotid Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Lung Neoplasms
1
Genetic Predisposition to Disease
1
Driving Under the Influence
1
Disease Progression
1
Disease
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Multiparametric Magnetic Resonance Imaging
×
Clear all
NCT04442724
2025-08-14
FMBRT
Cedars-Sinai Medical Center
Phase NA
Recruiting
60 enrolled
NCT07067749
2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3
Recruiting
92 enrolled